Autologous Stem Cell Transplant for Mantle Cell Lymphoma and the Transition Toward the Use of BTK Inhibitors Medscape InDiscussion: Mantle Cell Lymphoma

Drs Peter Martin and Brad Kahl discuss autologous stem cell transplantation for mantle cell lymphoma, the TRIANGLE trial results, and the transition toward use of Bruton tyrosine kinase inhibitors.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982888). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma https://ashpublications.org/blood/article/138/Supplement%201/815/480037/Long-Term-Follow-up-of-the-Resort-Study-E4402-A
Phase 2 Study of VcR-CVAD With Maintenance Rituximab for Untreated Mantle Cell Lymphoma: An Eastern Cooperative Oncology Group Study (E1405) https://pubmed.ncbi.nlm.nih.gov/24458437/
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network https://ascopubs.org/doi/abs/10.1200/JCO.22.01780
Ten-Year Follow-up After Intense Chemoimmunotherapy With Rituximab-HyperCVAD Alternating With Rituximab-High Dose Methotrexate/Cytarabine (R-MA) and Without Stem Cell Transplantation in Patients With Untreated Aggressive Mantle Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/20528872/
Mantle Cell Lymphoma https://emedicine.medscape.com/article/203085-overview
Primary Results From the Double-Blind, Placebo-Controlled, Phase III SHINE Study of Ibrutinib in Combination With Bendamustine-Rituximab (BR) and R Maintenance as a First-Line Treatment for Older Patients With Mantle Cell Lymphoma (MCL). https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.17_suppl.LBA7502
Efficacy and Safety of Ibrutinib Combined With Standard First-Line Treatment or as Substitute for Autologous Stem Cell Transplantation in Younger Patients With Mantle Cell Lymphoma: Results From the Randomized Triangle Trial by the European MCL Network https://ashpublications.org/blood/article/140/Supplement%201/1/490022/Efficacy-and-Safety-of-Ibrutinib-Combined-with
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma https://clinicaltrials.gov/ct2/show/NCT02728531
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission https://clinicaltrials.gov/ct2/show/NCT03267433